Biogen says it will soon seek regulatory approval in the US for the "groundbreaking" drug, called aducanumab. It plans to file the paperwork in early 2020 and has its sights on Europe too.

Aducanumab does not appear to be effective at treating adults with early-stage symptoms, the EMA said. Alzheimer's charities say they are disappointed by the decision because thousands of people ...

From the beginning, the approval of its Aduhelm (aducanumab) treatment was met with controversy – over the interactions with the FDA, and the advisor committee’s vote against the treatment ...

Anti-amyloid-beta monoclonal antibody treatments, such as aducanumab and lecanemab, have proven to be effective in clearing ...

Aduhelm generated hopes in the public and medical community alike when it was developed several years ago under the name aducanumab by Biogen Inc., but disappointing results from initial trials of the ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

A preprint research letter linking the Alzheimer's drug lecanemab (Leqembi) with excess deaths was withdrawn last week. The ...

An advisory committee to the Ministry of Health, Labour and Welfare (MHLW) has declined to approve Aduhelm (aducanumab), saying the data from its two main clinical trials is hard to interpret ...